• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bristol-Myers Squibb (NY: BMY )

    54.32 -1.45 (-2.60%)
    Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Bristol-Myers Squibb

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
    From Bristol Myers Squibb
    Via Business Wire
    U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
    From Bristol Myers Squibb
    Via Business Wire
    Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
    From Prime Medicine, Inc.
    Via GlobeNewswire
    U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
    From Bristol Myers Squibb
    Via Business Wire
    Analysts Think There's Still Time to Get in on Edgewise, Up 332%
    Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run? 
    Via MarketBeat
    New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Announces Dividend
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
    From Bristol Myers Squibb
    Via Business Wire
    Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb to Participate in Upcoming Investor Conferences
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
    From Bristol Myers Squibb
    Via Business Wire
    Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
    Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, 
    Via MarketBeat
    Topics Intellectual Property
    Exposures Intellectual Property
    European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
    From Bristol Myers Squibb
    Via Business Wire
    MarketBeat Week in Review – 7/29 - 8/2
    The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move 
    Via MarketBeat
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Pharma Giant's Shares Up After Impressive Q2 Earnings Release
    Bristol-Myers Squibb shares were up big on the day of its earnings release. The company beat adjusted EPS estimates and saw strong growth from many drugs. 
    Via MarketBeat
    Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
    From Bristol Myers Squibb
    Via Business Wire
    European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Announces Dividend
    From Bristol Myers Squibb
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.